A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

Phase 4

Not yet recruiting

• Conditions: Dry Eye Disease
• Interventions: Drug: Vevye®; Drug: Xiidra®

• Registration Number: NCT07025811
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).

Detailed Description

This study aims to characterize longitudinal changes in signs, symptoms, molecular, and imaging markers of the ocular surface to investigate pathological mechanisms and biomarkers (BMs) of DED after treatment with either of two commercially approved therapeutics (Vevye® \[cyclosporine ophthalmic solution\], Xiidra® \[liftegrast ophthalmic solution\]).

Study Timeline

• Status Verified: 2025-06
• Study First Submitted: 2025-06-16
• Study First Submitted QC: 2025-06-16
• Last Update Submitted: 2025-06-16
• Study First Posted: 2025-06-18
• Last Update Posted: 2025-06-18
• Study Start: 2025-07-31
• Primary Completion: 2026-04-30
• Study Completion: 2026-04-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

A. Inclusion Criteria for Participants with DED:

• The participant reported dry eye-related ocular symptoms for at least 6 months before the screening visit
• The participant must have either used lubricant eye drops regularly OR had the desire to use lubricant eye drops in the past 3 months
• Participant must be classified as having moderate/severe DED
• The participant is deemed by the physician to require a prescription medication for DED (e.g., cyclosporin A or lifitegrast)

B. Inclusion Criteria for Healthy Volunteers:

• The participant does not have overt clinical signs of DED in either eye

Exclusion Criteria

• Intraocular pressure (IOP) >21.00 millimeters of mercury (mmHg) in either eye
• Acute allergic conjunctivitis in either eye within 3 months prior to screening
• Use of contact lenses within 30 days prior to screening
• Current punctal plugs or punctal cauterization or occlusion
• Use of ocular anti-inflammatory agents or ocular immunosuppressive agents within 3 months prior to screening
• Any intraocular injections (e.g., intravitreal [IVT] anti-vascular endothelial growth factor [VEGF]) within 3 months prior to screening, or such injections planned for within the study period
• Any intraocular immunosuppressive implants within 12 months prior to screening
• Any history of isotretinoin use within 12 months prior to screening
• Uncontrolled ocular or systemic disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vevye®	Vevye®	Participants with evaporative dry eye (EDE), aqueous deficient dry eye (ADDE) and mixed dry eye will receive Vevye®, 1 milligrams per milliliter (mg/mL) as one drop into the affected eye(s), twice daily (BID) via topical ocular instillation for 12 weeks.
Xiidra®	Xiidra®	Participants with EDE, ADDE, and mixed dry eye will receive Xiidra®, 50 mg/mL as one drop into the affected eye(s), BID via topical ocular instillation for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Corneal Staining as Measured by Sodium Fluorescein	Up to Week 12